New antibody shows promise for tough thyroid eye disease
NCT ID NCT06269393
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a drug called IBI311 in 53 people with thyroid eye disease that did not get better with steroids. The drug is a modified antibody that blocks a specific receptor. The main goal was to see if it could reduce eye bulging. The trial was completed and compared IBI311 to a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IBI311 (a modified antibody that blocks IGF-1 receptors)
- What this could lead to
- If successful, this could offer a new treatment option for people with thyroid eye disease who do not respond well to steroids.
- What could go wrong
- This is an early exploratory study with only 53 participants, so results may not apply to everyone. The drug may cause side effects or fail to show clear benefit over placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID ASSOCIATED OPHTHALMOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100034, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.